MedPath

Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer

Phase 3
Terminated
Conditions
Cancer
Interventions
Registration Number
NCT01132547
Lead Sponsor
University of South Florida
Brief Summary

RATIONALE: Cyproheptadine hydrochloride may prevent weight loss caused by cancer or cancer treatment. It is not yet known whether cyproheptadine is more effective than a placebo in preventing weight loss in young patients receiving chemotherapy for cancer.

PURPOSE: This randomized phase III trial is studying cyproheptadine hydrochloride to see how well it works in preventing weight loss in young patients receiving chemotherapy for cancer.

Detailed Description

OBJECTIVES:

Primary

* To determine the effect of cyproheptadine hydrochloride in the prevention of cancer- or treatment-related weight loss (defined as ≥ 5% reduction in weight from baseline measurement) in children who are initiating a course of moderately or highly emetic chemotherapy.

Secondary

* To investigate the effect of cyproheptadine HCl on the change in weight for age scores after 8 weeks of study drug administration in comparison to placebo.

* Investigate the relationship between the secondary outcome variables (prealbumin, triceps skin fold, mid-upper arm circumference, and weight loss)from baseline to end of treatment in each group (treatment and placebo) separately.

OUTLINE: This is a multicenter study. Patients are stratified according to enrolling center and steroid use with cancer treatment (yes vs no). Study agent can start anytime up to and including day 28 after the first dose of chemotherapy.

* Arm I: Patients receive oral cyproheptadine hydrochloride twice daily for 8 weeks.

* Arm II: Patients receive an oral placebo twice daily for 8 weeks.

Patients undergo weight and height measurements at baseline and at each follow-up visit in weeks 4 and 8 to evaluate the effect of cyproheptadine hydrochloride and duration of response. Patients or parents complete medicine logs at each follow-up visit in weeks 4 and 8 to evaluate drug compliance and tolerance. Patients also undergo measures of nutrition; and measures of body composition, lean body mass, and fat percentage using standardized equipment and procedures for measuring triceps skin fold and mid-arm muscle circumference at baseline and at the end of the study.

Patients undergo blood sample collection at baseline and at the end of the study for biomarker studies. Samples are analyzed for pre-albumin levels.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
22
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Arm II placeboplaceboPatients receive an oral placebo twice daily for 8 weeks.
Arm I cyproheptadine hydrochloridecyproheptadine hydrochloridePatients receive oral cyproheptadine hydrochloride twice daily for 8 weeks.
Primary Outcome Measures
NameTimeMethod
Participant With Weight Loss ≥ 5% at the 8- Week Assessment When Compared to Baseline8 weeks
Severity of Weight LossBaseline and 8 weeks

Change from Baseline in Weight Z score

Secondary Outcome Measures
NameTimeMethod
Pattern of Weight in the Study PopulationBaseline and 8 weeks

Change from Baseline in Weight

Trial Locations

Locations (14)

Connecticut Children's Medical Center

🇺🇸

Hartford, Connecticut, United States

Children's Hospital of Southwest Florida at Lee Memorial

🇺🇸

Fort Myers, Florida, United States

Miller Children's Hospital

🇺🇸

Long Beach, California, United States

A.I. duPont Hospital for Children

🇺🇸

Wilmington, Delaware, United States

Children's National Medical Center

🇺🇸

Washington, District of Columbia, United States

Arnold Palmer Hospital for Children

🇺🇸

Orlando, Florida, United States

Nemours Children's Hospital Pensacola

🇺🇸

Pensacola, Florida, United States

Nemours Children's Clinic - Orlando

🇺🇸

Orlando, Florida, United States

Ochsner Clinic Foundation

🇺🇸

New Orleans, Louisiana, United States

CHRISTUS Santa Rosa Children's Hospital

🇺🇸

San Antonio, Texas, United States

Columbia University Medical Center

🇺🇸

New York, New York, United States

Children's Hospital of The King's Daughters

🇺🇸

Norfolk, Virginia, United States

Kapiolani Medical Center for Women and Children

🇺🇸

Honolulu, Hawaii, United States

Nemours Children's Clinic - Jacksonville

🇺🇸

Jacksonville, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath